437 related articles for article (PubMed ID: 30151728)
1. Treatment of Diabetes in Patients with Heart Failure.
Bowes CD; Lien LF; Butler J
Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
4. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
5. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
6. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
7. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Nassif ME; Kosiborod M
Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
[TBL] [Abstract][Full Text] [Related]
8. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
9. [Novel antidiabetic drugs and cardiovascular complications].
Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?
Bowes CD; Lien LF; Butler J
Curr Diab Rep; 2019 May; 19(7):39. PubMed ID: 31127397
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A; Lanzinger S; Chia-Hui Tan E; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Ha KH; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; Nyström T; Niskanen L; Linnemann Jensen M; Hoti F; Klement R; Déruaz-Luyet A; Kyaw MH; Koeneman L; Vistisen D; Carstensen B; Halvorsen S; Langslet G; Fazeli Farsani S; Patorno E; Núñez J;
Diabetes Metab; 2023 Mar; 49(2):101418. PubMed ID: 36608816
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Bailey CJ; Marx N
Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P
Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
16. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
Libianto R; Davis TM; Ekinci EI
Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
[TBL] [Abstract][Full Text] [Related]
18. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
North EJ; Newman JD
Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
[TBL] [Abstract][Full Text] [Related]
19. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
20. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
